US food benefits for the poor to be reduced as pandemic provisions end

Published Date: 02 Mar 2023

As the federal government ends pre-approved benefits during the early stages of the COVID-19 pandemic, low-income Americans could receive less food assistance or lose their eligibility altogether.

Read Full News

Latest News

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Joshua Wechsler, MD, on dupilumab's sustained efficacy in pediatric patients with EoE Joshua Wechsler, MD, MSCI

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Rimegepant Linked to Increased Rectal Compliance, Reduced Rectal Sensation in IBS, With Ayah Matar, MD Ayah Matar, MD

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Todays Updates

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias Louie Pasculli

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026 Kathrin LaFaver, MD, FAAN, DipABLM, Isabella Ciccone, MPH

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

Todays Updates

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias Louie Pasculli

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026 Kathrin LaFaver, MD, FAAN, DipABLM, Isabella Ciccone, MPH

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

Latest News

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

News All Time

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Conference Preview: American College of Gastroenterology’s 2025 Annual Scientific Meeting Abigail Brooks, MA

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

Recommended News For You

Smart exercise planning could boost recovery for people with cancer

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

Parkinson patient's gait is restored by a spinal cord stimulator.

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

New study links air pollution with higher rates of head and neck cancer

improvements in the treatment of prostate cancer resistant to chemotherapy.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

Recommended Articles For You

Anemia Symptoms: What You Need to Know  

Unraveling the Genetic Mystery of Hereditary Spherocytosis 

Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers 

Angina Haemorrhagica Bullosa: What You Need to Know 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.

2.

Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco

3.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

4.

High numbers of rural patients cross state lines for cancer care

5.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

1.

How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?

2.

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed

3.

Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment

4.

The Benefits and Risks of Transurethral Resection of Bladder Tumor 

5.

The Science Behind Imatinib: How It Targets Cancer Cells 

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

2.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot